Aim immunotech's ampligen featured in peer-reviewed journal cancers as a potential therapy for cancer patients with sars-cov-2

The netherlands grants aim a patent for ampligen as a cancer therapy for use in combination with checkpoint blockade inhibitors the netherlands grants aim a patent for ampligen as a cancer therapy for use in combination with checkpoint blockade inhibitors
AIM Ratings Summary
AIM Quant Ranking